|
14 Oct 2019 |
Ultragenyx Announces FDA Accepts New Drug Application for UX007 (triheptanoin) for Treatment of Long-chain Fatty Acid Oxidation Disorders
|
|
14 Oct 2019 |
I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China
|
|
14 Oct 2019 |
U.S. FDA Approves XARELTO® (rivaroxaban) to Help Prevent Blood Clots in Acutely Ill Medical Patients
|
|
14 Oct 2019 |
DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease
|
|
14 Oct 2019 |
Femtogenix Presents Efficacy and Toxicity Data on Antibody Drug Conjugates Containing New Generation of DNA-binding Therapeutic Payloads
|
|
14 Oct 2019 |
Phase III PEMPHIX Study Shows Genentech’s Rituxan (Rituximab) Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris
|
|
13 Oct 2019 |
Lilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval
|
|
12 Oct 2019 |
Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration
|
|
12 Oct 2019 |
Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo
|
|
12 Oct 2019 |
Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV Congress
|
|
12 Oct 2019 |
Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to Severe Atopic Dermatitis
|
|
11 Oct 2019 |
Eyevensys Presents Initial Data from Phase I/II Trial of Innovative, Non-Viral Gene Therapy for Ocular Diseases at 11th Annual Ophthalmology Innovation Summit
|
|
11 Oct 2019 |
Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
|
|
11 Oct 2019 |
Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration
|
|
11 Oct 2019 |
Kangpu Biopharmaceuticals Successfully Completed Phase I Study of Novel CRL4-CRBN Modulator KPG-818 in the U.S.
|
|
11 Oct 2019 |
Shionogi enters into a new license agreement and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc.
|
|
11 Oct 2019 |
PanOptica Anti-VEGF Eye Drop Shows Promise in Treatment of Neovascular (Wet) AMD
|
|
11 Oct 2019 |
Aerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma
|
|
11 Oct 2019 |
Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis
|
|
11 Oct 2019 |
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of CAR-T Associated Neurotoxicity
|
